{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:48:05Z","timestamp":1791827285221,"version":"4.3.4"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejmech.2018.10.066","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T21:44:28Z","timestamp":1541195068000},"page":"612-630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase"],"prefix":"10.1016","volume":"162","author":[{"given":"Mei-Jung","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-0726","authenticated-orcid":false,"given":"Hsueh-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony Eight","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Nepali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Yang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-6405","authenticated-orcid":false,"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.10.066_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00018-008-8539-7","article-title":"Therapeutic protein kinase inhibitors","volume":"66","author":"Grant","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2018.10.066_bib2a","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1021\/acs.jmedchem.6b00463","article-title":"Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth","volume":"59","author":"P\u00e9rez-P\u00e9rez","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib2b","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1021\/acs.jmedchem.6b00101","article-title":"Novel combretastatin-2-aminoimidazole analogues as potent tubulin assembly inhibitors: exploration of unique pharmacophoric impact of bridging skeleton and aryl moiety","volume":"59","author":"Chaudhary","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib2c","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/acs.jmedchem.5b01086","article-title":"Synthesis and biochemical evaluation of 3-phenoxy-1,4-diarylazetidin-2-ones as tubulin-targeting antitumor agents","volume":"59","author":"Greene","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib2d","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1021\/acs.jmedchem.6b01268","article-title":"Potent antitumor activities and structure basis of the chiral \u03b2-lactam bridged analogue of combretastatin A-4 binding to tubulin","volume":"59","author":"Zhou","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib3a","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1074-5521(96)90129-5","article-title":"Understanding and controlling the cell cycle with natural products","volume":"3","author":"Hung","year":"1996","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.10.066_bib3b","first-page":"522","article-title":"Current development status of small-molecule vascular disrupting agents","volume":"7","author":"Chaplin","year":"2006","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2018.10.066_bib3c","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1021\/jm0512903","article-title":"Medicinal chemistry of combretastatin A4: present and future directions","volume":"49","author":"Tron","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib3d","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/13543776.12.11.1663","article-title":"Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer","volume":"12","author":"Li","year":"2002","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.10.066_bib3e","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/13543784.2016.1189901","article-title":"Early investigational tubulin inhibitors as novel cancer therapeutics","volume":"25","author":"Nepali","year":"2016","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2018.10.066_bib4a","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/cr960095g","article-title":"CC-1065 and the duocarmycins: synthetic studies","volume":"97","author":"Boger","year":"1997","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.10.066_bib4b","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1016\/j.tetlet.2015.11.010","article-title":"Stereoselective synthesis of cis-2,3-disubstituted indolines via an aza-alkylation\/Michael cascade reaction","volume":"56","author":"Mirim","year":"2015","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2018.10.066_bib5","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1016\/j.bmcl.2012.08.054","article-title":"1-(Sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"12","author":"Yacovan","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.10.066_bib6a","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/jm061076u","article-title":"7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents","volume":"49","author":"Chang","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib6b","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/jpet.107.126680","article-title":"A\u00a0novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in\u00a0vitro and in\u00a0vivo through the disruption of microtubule","volume":"323","author":"Liou","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.10.066_bib7","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1016\/j.ejmech.2011.03.067","article-title":"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides","volume":"46","author":"Raffa","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2014.01.053","article-title":"Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere","volume":"75","author":"Shao","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib9","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1016\/j.bmc.2015.08.007","article-title":"Discovery of 4-benzoylamino-N-(prop-2-yn-1-yl)benzamides as novel microRNA-21 inhibitors","volume":"23","author":"Jiang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib10","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib11","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.96.8.4592","article-title":"A\u00a0synthetic inhibitor of histone deacetylase, MS-27-275, with marked in\u00a0vivo antitumor activity against human tumors","volume":"96","author":"Saito","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.10.066_bib12","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/jm7011408","article-title":"Histone deacetylase inhibitors: from bench to clinic","volume":"51","author":"Marielle","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1124\/jpet.103.055541","article-title":"Identification of novel isoform-selective inhibitors within class I histone deacetylases","volume":"21","author":"Hu","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.10.066_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","article-title":"MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Fournel","year":"2008","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2018.10.066_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3727\/096504005775082066","article-title":"In\u00a0vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines","volume":"15","author":"Loprevite","year":"2005","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2018.10.066_bib16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1039\/C5OB02100F","article-title":"2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition","volume":"14","author":"Nepali","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib17a","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.ejmech.2016.11.033","article-title":"3-Aroylindoles display antitumor activity in\u00a0vitro and in\u00a0vivo: effects of N1-substituents on biological activity","volume":"125","author":"Lee","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib17b","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fphar.2018.00205","article-title":"A\u00a0novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in\u00a0vitro and in\u00a0vivo","volume":"13","author":"Wu","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.10.066_bib17c","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejmech.2015.03.035","article-title":"Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors","volume":"95","author":"Zhang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib17d","doi-asserted-by":"crossref","first-page":"40444","DOI":"10.1039\/C4RA05508J","article-title":"Design, synthesis and biological evaluation of 4\u2032-demethyl-4-deoxypodophyllotoxin derivatives as novel tubulin and histone deacetylase dual inhibitors","volume":"4","author":"Zhang","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.10.066_bib17e","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jmgm.2016.10.007","article-title":"A\u00a0comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors","volume":"70","author":"Hassanzadeh","year":"2016","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2018.10.066_bib17f","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1016\/j.bmc.2013.03.049","article-title":"The discovery of colchicine-SAHA hybrids as a new class of antitumor agents","volume":"21","author":"Zhang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib17g","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1021\/acs.jmedchem.8b00050","article-title":"Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4","volume":"61","author":"Lamaa","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib18a","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2191-2858-3-3","article-title":"Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors","volume":"3","author":"Kumar","year":"2013","journal-title":"Org. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.10.066_bib18b","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1158\/0008-5472.CAN-03-3474","article-title":"BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in\u00a0vivo","volume":"64","author":"Kuo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.10.066_bib18c","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1016\/j.ejmech.2011.04.065","article-title":"Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents","volume":"46","author":"Lai","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib18d","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1021\/jm4011115","article-title":"Furanylazaindoles: potent anticancer agents in\u00a0vitro and in\u00a0vivo","volume":"56","author":"Lee","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib19a","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1021\/jm300197a","article-title":"Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in\u00a0vivo","volume":"55","author":"Lai","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib19b","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejmech.2017.03.079","article-title":"4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in\u00a0vitro and in\u00a0vivo","volume":"134","author":"Mehndiratta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib19c","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2014.08.020","article-title":"Indole-3-ethylsulfamoylphenylacrylamides: potent histone deacetylase inhibitors with anti-inflammatory activity","volume":"85","author":"Mehndiratta","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib19d","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejmech.2016.12.039","article-title":"Ring-opened tetrahydro-\u03b3-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms","volume":"127","author":"Nepali","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.10.066_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejmech.2014.02.061","article-title":"Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones","volume":"77","author":"Chang","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib22","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1021\/jm201031f","article-title":"5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2","volume":"54","author":"Lee","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib23","unstructured":"B. LeadIT, http:\/\/www.biosolveit.de\/LeadIT. accessed 12th Mar 2011."},{"key":"10.1016\/j.ejmech.2018.10.066_bib24","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1021\/acs.bioconjchem.6b00353","article-title":"Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action","volume":"27","author":"Huang","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/157340641003140304144930","article-title":"Structural analysis for colchicine binding site-targeted ATCAA derivatives as melanoma antagonists","volume":"10","author":"Zhang","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib26","unstructured":"Forge, 10.4.2; Cresset: Litlington, Cambridgeshire, UK."},{"key":"10.1016\/j.ejmech.2018.10.066_bib27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.10.066_bib28","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1016\/j.bmcl.2012.09.093","article-title":"The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position","volume":"22","author":"Choi","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.10.066_bib29","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1535-7163.MCT-10-0779","article-title":"Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor","volume":"10","author":"Kong","year":"2011","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2018.10.066_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jsb.2016.06.023","article-title":"Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket","volume":"195","author":"Tabackman","year":"2016","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.ejmech.2018.10.066_bib31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/14656566.2017.1316374","article-title":"Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer","volume":"18","author":"Hardin","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2018.10.066_bib32","first-page":"37","article-title":"Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung cancer: where are we now and what should we expect?","volume":"38","author":"Damaskos","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2018.10.066_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/157488406775268200","article-title":"Current state of the art of new tubulin inhibitors in the clinic","volume":"1","author":"Kuppens","year":"2006","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.10.066_bib34","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.10.066_bib35","first-page":"85","article-title":"Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma","volume":"9","author":"Guo","year":"2012","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ejmech.2018.10.066_bib36a","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s002800100322","article-title":"Histone deacetylases and transcriptional therapy with their inhibitors","volume":"48","author":"Pandolfi","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.10.066_bib36b","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/jm901453q","article-title":"Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-Nhydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer","volume":"53","author":"Cai","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.10.066_bib38","first-page":"22","article-title":"Romidepsin for the treatment of peripheral T-celllymphoma","volume":"6","author":"Barbarotta","year":"2015","journal-title":"J.\u00a0Adv. Pract. Oncol."},{"key":"10.1016\/j.ejmech.2018.10.066_bib39","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/ijc.23243","article-title":"Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer","volume":"122","author":"Qian","year":"2008","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2018.10.066_bib40","first-page":"185","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China, Intractable Rare","volume":"5","author":"Lu","year":"2016","journal-title":"Dis. Res."},{"key":"10.1016\/j.ejmech.2018.10.066_bib41","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.18632\/oncotarget.3213","article-title":"Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in\u00a0vitro and in\u00a0vivo","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.10.066_bib42","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1158\/0008-5472.CAN-03-3474","article-title":"BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in\u00a0vivo","volume":"64","author":"Kuo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.10.066_bib43","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1021\/jm900685y","article-title":"5-Amino-2-Aroylquinolines as highly potent tubulin polymerization inhibitors","volume":"53","author":"Nien","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib44","first-page":"2325","article-title":"Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.10.066_bib45a","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2144\/00291rr02","article-title":"Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin","volume":"29","author":"Tahir","year":"2000","journal-title":"Biotechniques"},{"key":"10.1016\/j.ejmech.2018.10.066_bib45b","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/jm0305974","article-title":"Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents","volume":"47","author":"Liou","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib46a","first-page":"5480","article-title":"A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors","volume":"61","author":"Tahir","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.10.066_bib46b","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1432-1033.1980.tb04835.x","article-title":"Quantitative analysis of tubulin colchicine binding to microtubules","volume":"109","author":"Lambier","year":"1980","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2018.10.066_bib47","first-page":"227","article-title":"Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative","volume":"2","author":"Tahir","year":"2003","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2018.10.066_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein Data Bank","volume":"28","author":"M Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2018.10.066_bib49","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.drudis.2014.02.003","article-title":"Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde?","volume":"19","author":"Cruz-Monteagudo","year":"2014","journal-title":"Drug Discov. Today"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418309437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418309437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:51:06Z","timestamp":1759326666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418309437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":73,"alternative-id":["S0223523418309437"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.066","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}